肾缺血再灌注损伤时血栓素/前列环素的动态变化及川芎嗪的调控作用

中国临床药理学与治疗学 ›› 2009, Vol. 14 ›› Issue (6): 637-641.

肾缺血再灌注损伤时血栓素/前列环素的动态变化及川芎嗪的调控作用

毛朝鸣¹, 陈辉乐¹, 王万铁², 金可可², 邱晓晓², 谢克俭³

¹温州医学院附属第二医院肾内科,²病理生理学教研室,³检验医学与公共卫生学院放免中心, 温州 325035, 浙江

收稿日期:2009-03-04 修回日期:2009-05-25 出版日期:2009-06-26 发布日期:2020-10-27
作者简介:毛朝鸣,男,副主任医师,主要从事肾脏缺血再灌注损伤基础研究及肾脏病临床诊治。 E-mail:maochaoming@126.com
基金资助:
浙江省教育厅科研基金资助项目(19990444)

Regulatory effect of ligustrazine on the dynamic change of thromboxane/prostacyclin in renal ischemia reperfusion injury rabbits

MAO Chao-ming¹, CHEN Hui-le¹, WANG Wan-tie², JIN Ke-ke², QIU Xiao-xiao², XIE Ke-jian³

¹Department of Nephrology, the Second Affiliated Hospital of Wenzhou Medical College;
²Department of Morbid Physiology;
³Radioimmune Center of Laboratory Medical Science & Public Health, Wenzhou 325035, Zhejiang, China

Received:2009-03-04 Revised:2009-05-25 Online:2009-06-26 Published:2020-10-27

摘要/Abstract

摘要： 目的: 观察兔肾缺血再灌注损伤时血栓素/前列环素体系的动态变化, 探讨中药川芎嗪注射液的调控作用及机制。方法: 日本大耳白兔30只, 随机均分为3 组:假手术组、再灌注组、川芎嗪组。复制在体兔肾缺血再灌注损伤动物模型, 在缺血前、缺血1 h、再灌注1、3、5 h 分别经颈总动脉抽血检测血栓素B₂ (TXB₂) 和6-酮-前列腺素F_1α(6-keto-PGF_1α) 含量, 计算其比值;实验结束时取肾组织检测TXB₂ 和6-keto-PGF_1α含量与比值。结果: 再灌注组血浆TXB₂ 含量随缺血和再灌注时间的延长呈阶梯性升高, 与假手术组各时点相比均明显升高(均P<0.01);川芎嗪组血浆TXB₂ 含量与再灌注组及假手术组同时相点比较, 均明显下降(均P<0.01) 。川芎嗪组血浆TXB₂ 6-keto-PGF_1α在缺血和再灌注各时点与假手术组相比差异均无统计学意义(均P>0.05), 但均显著低于再灌注组(均P<0.01) 。川芎嗪组与再灌注组比较肾组织TXB₂、TXB₂ 6-keto-PGF_1α下降非常明显(均P<0.01), 6-keto-PGF_1α差异无统计学意义(P>0.05) 。结论: 川芎嗪能抑制血小板释放TXA₂,调控TXA₂/PGI₂ 的平衡, 遏制无复流现象, 故可减轻肾缺血再灌注损伤。

关键词: 川芎嗪, 肾, 缺血再灌注损伤, 血栓素A₂, 前列环素

Abstract: AIM: To investigate the dynamic change of thromboxane prostacyclin in renal ischemia reperfusion injury rabbits, and approach the regulatory effects of ligustrazine injection on renal ischemia reperfusion injury and its mechanisms. METHODS: Thirty rabbits were divided into three groups randomly:sham operation group (group S), ischemia reperfusion injury group (group IR) and ischemia reperfusion injury plus ligustrazine injection group (group LZ), each group had ten rabbits.The renal ischemia reperfusion injury model of rabbit was established in vivo.The content of thromboxane B₂ (TXB₂), 6-keto-prostaglandin F_1α(6-keto-PGF_1α) were detected in the blood plasma gathered from common carotid artery at times:pre-ischemia, ischemia 1 h, reperfusion 1, 3 and 5 h, the ratio of TXB₂ and 6-keto-PGF_1αwere calculated.The content and the ratio of TXB₂ and 6-keto-PGF_1α in kidney tissue were detected at the end of the experiment. RESULTS: The content of TXB₂ in plasma showed a time-dependent ascensus in group IR during ischemia reperfusion, it was significant higher than that in group S at all time points (all P<0.01).Compared withgroup IR and with group S, the content of TXB₂ in plasma was decreased significantly in group LZ at each time point during ischemia reperfusion (all P<0.01). Compared with group S, there was not different significance for the TXB₂ 6-keto-PGF_1α in group LZ(all P> 0.05).Compared with group IR, it was significant lower in group LZ at each of time point (all P<0.01). Compared with group IR, in group LZ, the TXB₂ level and TXB₂ 6-keto-PGF_1α in kidney tissue were decreased remarkably (all P<0.01), there was no different significances in 6-keto-PGF_1α (P>0.05). CONCLUSION: Ligustrazine could inhibit platelet to release TXA₂, regulate the balance of TXA₂/PGI₂, restrain no reflow phenomenon, so it could prevent renal ischemia reperfusion injury.

Key words: ligustrazine, kidney, ischemia reperfusion injury, thromboxane A₂, prostacyclin

中图分类号:

R965.2

毛朝鸣, 陈辉乐, 王万铁, 金可可, 邱晓晓, 谢克俭. 肾缺血再灌注损伤时血栓素/前列环素的动态变化及川芎嗪的调控作用[J]. 中国临床药理学与治疗学, 2009, 14(6): 637-641.

MAO Chao-ming, CHEN Hui-le, WANG Wan-tie, JIN Ke-ke, QIU Xiao-xiao, XIE Ke-jian. Regulatory effect of ligustrazine on the dynamic change of thromboxane/prostacyclin in renal ischemia reperfusion injury rabbits[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(6): 637-641.

参考文献

[1] Erdogan H, Fadillioglu E, Yagmurca M, et al.Protein oxidation and lipid peroxidation after renal ischemia-reperfusion injury:Protective effects of erdostein and N-acetylcysteine[J].Urol Res, 2006, 34(1):41-46.
[2] 陈辉乐.川芎嗪与肾脏疾病的研究进展[J].现代中西医结合杂志, 2008, 17(15):2410-2413.
[3] 徐正衸, 王万铁, 李东, 等.川芎嗪对肝缺血再灌注损伤脂质过氧化的影响[J].中国应用生理杂志,2002, 18(2):173-175.
[4] Clapp LH, Finney P, Turcato S, et al.Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery [J].Am J Respire Cell Mol Biol, 2002, 26(2):194-201.
[5] WestonMW, Isaac BF, Crain C.The use of inhaled prostacyclin in nitroprusside-resistant pulmonary artery hypertension[J].J Heart Lung Transplant, 2001, 20(12):1340-1344.
[6] Kohyama T, Liu X, Wen FQ, et al.Potentiation of human lung fibroblast chemotaxis by the thromboxane A2 analog U-46619[J].J Lab Clin Med, 2002, 139(1):43-49.
[7] Cheng Y, Austin SC, Rocca B, et al.Role of prostacyclin in the cardiovascular response to thromboxane A2[J]. Science, 2002, 19, 296(5567):539-541.
[8] Kobayashi T, Tahara Y, Matsumoto M, et al.Roles of thromboxane A(2) and prostacy clin in the development of atherosclerosis in apoE-deficient mice[J].J Clin Invest, 2004, 114(6):784-794.
[9] Evangelista V, Dell'Elba G, Celardo A, et al.TXA₂-mediated myocardial ischemia as a consequence of an acute lung inflammatory reaction in the rabbit[J].J Thromb Haemost, 2003, 1(2):314-319.
[10] Sui DY, Qu SC, Yu XF, et al.Protective effect of ASS on myocardial ischemia-reperfusion injury in rats[J]. Zhongguo Zhong Yao Za Zhi, 2004, 29(1):71-74.
[11] Hirose K, Okajima K, Uchiba M, et al.Antithrombin reduces the ischemia reperfusion induced spinal cord injury in rats by attenuating inflammatory responses[J].Thromb Haemost, 2004, 91(1):162-170.
[12] 徐正衸, 王万铁, 谢克俭.心肌缺血再灌注损伤时PGI₂ TXA₂ 的变化及川芎嗪的调控作用[J].温州医学院学报, 1997, 27(2):129-131.

[1]	许宜琪, 吴茜, 刘书, 刘帆, 邢春燕, 李勤, 何俊俊, 何春玲, 赵咏莉, 高家林. 雷公藤多苷治疗糖尿病肾脏病的临床疗效及抗炎抗纤维化分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1034-1042.
[2]	汪飞, 杭永付, 王未. 重症患者肾功能亢进对替考拉宁血药浓度影响分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1043-1048.
[3]	李士旭, 李林运, 王新, 李轲, 卞华. 银杏叶提取物通过miR-145/FOXO1轴对实验性肾功能衰竭大鼠肾脏损伤的影响[J]. 中国临床药理学与治疗学, 2023, 28(7): 728-735.
[4]	李坤, 李璐璐, 李楠楠, 胡卫红, 周建超. 成人肾移植术后血糖控制和CYP3A5基因多态性对他克莫司谷浓度的影响[J]. 中国临床药理学与治疗学, 2023, 28(7): 767-774.
[5]	王娟, 刘维英, 叶育才, 付文丽, 张莎, 李乐萍. 去甲肾上腺素再摄取抑制剂联合抗毒蕈碱剂治疗阻塞性睡眠呼吸暂停的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 714-720.
[6]	党子龙, 刘海洋, 张扬帆, 刘金凤, 张天为, 李斌, 郭鸿, 成文媛, 许晓辉, 李一乐, 魏玉辉, 武新安. 肾功能亢进ICU患者的抗菌药物给药方案调整策略研究进展[J]. 中国临床药理学与治疗学, 2023, 28(5): 561-571.
[7]	张明康, 马彦荣, 靳永文, 周燕, 崔睿睿, 武新安. 药源性急性间质性肾炎的临床研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 419-428.
[8]	宁思思, 赵玉红, 颜蕾, 唐敏娜, 张凝之, 张泳巧, 崔兆强. 高血压合并慢性肾脏病患者的降压目标之争议[J]. 中国临床药理学与治疗学, 2023, 28(4): 463-467.
[9]	马月, 马旺博, 周智华, 常静雯, 范方田. 槲皮素干预肾间质成纤维细胞糖酵解抗肾间质纤维化机制研究[J]. 中国临床药理学与治疗学, 2023, 28(2): 121-129.
[10]	侯小煜, 冷玉芳, 曹雪芬, 吕兴娇, 韩晓霞, Janvier NIBARUTA, 刘永强. 五味子乙素减轻小鼠肠缺血再灌注损伤的网络药理学分析及实验验证[J]. 中国临床药理学与治疗学, 2023, 28(2): 147-154.
[11]	张照伟, 李佐军, 黄坚, 李霜青, 何依玲. 临床药师在肾内科开展药学服务工作切入点的探索[J]. 中国临床药理学与治疗学, 2023, 28(2): 184-188.
[12]	曹雪芬, 冷玉芳, 韩晓霞, 侯小煜, 吕兴娇, Janvier NIBARUTA. 川芎嗪通过抑制NLRP3减轻肠缺血再灌注损伤的细胞焦亡[J]. 中国临床药理学与治疗学, 2023, 28(11): 1201-1208.
[13]	吴莉莉, 梁至, 黄思咏, 王妍. 肾功能亢进对感染性心内膜炎患者万古霉素药动学的影响及有效性与安全性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1139-1145.
[14]	杨治安, 赵岩, 何瑶, 刘维英, 余勤. 细胞焦亡介导慢性间歇缺氧大鼠肾脏损伤及依达拉奉的干预作用[J]. 中国临床药理学与治疗学, 2023, 28(1): 10-18.
[15]	徐涛, 朱素燕, 邱相君, 徐萍. 肾功能不全患者人群中替考拉宁群体药代动力学模型的建立与验证[J]. 中国临床药理学与治疗学, 2022, 27(9): 977-983.